Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
American Journal of Hematology|September 27, 2005
Hypereosinophilic syndrome: an updateH Jeffrey Wilkins, Martin M Crane, Kelly Copeland, et al.
Current Opinion in Pharmacology|May 14, 2004
Emerging therapeutic targets in psoriasisAndrew I Bayliffe, Richard A Brigandi, H Jeffrey Wilkins, et al.
The Journal of Clinical Investigation|December 6, 2021
Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndromeDavid S Perlin, Garry A Neil, Colleen Anderson, et al.
Gastrointestinal Endoscopy|August 19, 2020
Fully automated endoscopic disease activity assessment in ulcerative colitisHeming Yao, Kayvan Najarian, Jonathan Gryak, et al.
American Journal of Respiratory and Critical Care Medicine|August 20, 2011
Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled studyMario Castro, Sameer Mathur, Frederick Hargreave, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2019
Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor ActivityDevalingam Mahalingam, Judy S Wang, Erika P Hamilton, et al.
European Urology|July 6, 2006
Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled studyHartmut Porst, Ira D Sharlip, Dimitris Hatzichristou, et al.
Clinical Therapeutics|November 18, 2005
Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysisDimitrios G Hatzichristou, Philip Aliotta, Stephen Auerbach, et al.
BJU International|December 22, 2004
Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trialCulley C Carson, Dimitrios G Hatzichristou, Serge Carrier, et al.
The Journal of Allergy and Clinical Immunology|December 31, 2011
Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trialJonathan M Spergel, Marc E Rothenberg, Margaret H Collins, et al.
Pageof 1